1
40
4
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1542/peds.110.3.e34" target="_blank" rel="noreferrer">http://doi.org/10.1542/peds.110.3.e34</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs
Publisher
An entity responsible for making the resource available
Pediatrics
Date
A point or period of time associated with an event in the lifecycle of the resource
2002
Subject
The topic of the resource
Child; Female; Humans; Male; Non-U.S. Gov't; Research Support; Mental Retardation/complications; Antipsychotic Agents/therapeutic use; Child Behavior Disorders/complications/drug therapy; Dopamine Antagonists/therapeutic use; Risperidone/therapeutic use; Serotonin Antagonists/therapeutic use
Creator
An entity primarily responsible for making the resource
Turgay A; Binder C; Snyder R; Fisman S
Description
An account of the resource
OBJECTIVE: The objective of this study was to investigate the long-term safety and efficacy of risperidone in disruptive behavior disorders in children with subaverage IQs. Disruptive behavior disorders were defined as oppositional defiant disorder, disruptive behavior disorder, and conduct disorder as per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. METHODS: This was a 48-week open-label (OL) extension study of risperidone in 77 children diagnosed with a disruptive behavior disorder, and either borderline intellectual function or mild or moderate mental retardation who had participated in a previous 6-week, double-blind (DB) study and completed at least 2 weeks of DB therapy. Children, aged 5 to 12 years inclusive, who had: 1) a DSM-IV Axis I diagnosis of conduct disorder, oppositional defiant disorder, or disruptive behavior disorder- not otherwise specified; 2) a parent-assessed rating of > or =24 in the Conduct Problem Subscale of the Nisonger-Child Behavior Rating Form(28); 3) a DSM-IV Axis II diagnosis of mild or moderate mental retardation or borderline intellectual functioning with an IQ > or =36 and < or =84; and 4) a score of < or =84 on the Vineland Adaptive Behavior Scale. Participants received oral solution risperidone given at a once daily dose of between 0.02 and 0.06 mg/kg for a maximum of 48 weeks. Participants in the DB study who had been randomized would have had a maximum of 54 weeks of risperidone therapy. Study visits were scheduled at entry, weekly for the first month, and monthly for the remaining 11 months. RESULTS: Baseline scores on the conduct problem subscale at the start of the previous DB study were similar for both treatment groups: mean values of 33.5 and 33.3 were recorded for placebo- and risperidone-treated participants, respectively. At the time of the OL baseline visit, mean Conduct Problem Subscale scores were lower in those who had been treated with risperidone than in those who remained risperidone-naive (17.5 and 26.1, respectively). Within 1 week of receiving daily risperidone therapy (mean daily dose: 1.38 mg), those participants who had been risperidone-naive at OL entry showed a rapid improvement in the Conduct Problem Subscale score. At the week 1 assessment, the mean change from baseline for those who had been risperidone-naive at OL entry was similar in magnitude to the change from DB baseline recorded for participants who had received risperidone in the DB study. This mean improvement was sustained in both groups throughout the remainder of the OL study. At study endpoint, those participants who had been risperidone-naive at OL entry experienced a highly significant mean decrease from OL baseline in the mean Conduct Problem Subscale score of 10.6 +/- 2.18. The response to risperidone in the OL trial remained stable in those participants who had been treated with risperidone in the previous DB trial; in this group, the mean change at study endpoint from OL baseline was a nonsignificant decrease of 1.26 +/- 1.45. At DB baseline, 68% of participants had a Clinical Global Impression assessment rated as marked, severe, or extremely severe. By DB study endpoint, only 17% of participants (15% of whom had received placebo and 19% of whom had been treated with risperidone in the previous study) had this severe an assessment; 63% of participants had symptoms rated as either none, very mild, or mild. Similarly, highly significant decreases from baseline in the Vineland Adaptive Behavior Scale rating of the most troublesome symptom (often identified as either aggression (hitting, fighting, or temper tantrums) were observed by study endpoint after 48 weeks of risperidone therapy. For those participants who had received placebo in the previous study, a mean decrease of 47.1 +/- 4.87 mm from a DB baseline of 79.4 +/- 2.69 mm was observed. In those who had received risperidone, a mean decrease of 43.5 +/- 4.57 mm from a DB baseline of 79.3 +/- 3.66 mm was observed. Five subgroup analyses of the primary efficacy outcome were performed. These included analysis by diagnosis (conduct disorder, oppositional defiant disorder, and disruptive behavior disorder-not otherwise specified), degree of mental retardation (borderline, mild, moderate), and presence or absence of somnolence, attention-deficit/hyperactivity disorder, and psychostimulants. The results showed that the efficacy of risperidone was not affected by type of disorder, level of retardation, presence/absence of somnolence or attention-deficit/hyperactivity disorder, or use of psychostimulants. Adverse events were reported for 76 participants; none were serious and most were mild/moderate in severity. Somnolence (52%), headache (38%), and weight gain (36%) were the most common adverse events. The degree of sedation was mild and not associated with cognitive deterioration. In fact, for most parameters assessed on the modified California Verbal Learning Test (a test for verbal learning and memory), there were statistically significant improvements relative to both OL and DB baselines in the mean scores. In addition, statistically significant improvements over baseline were also seen for some Continuous Performance Task (which is a test for attention and impulsivity) parameters. Overall, no deterioration of cognitive function was observed while participants were treated with risperidone. Almost half of the 8.5 kg gained was attributable to normal growth. Asymptomatic peak prolactin levels were observed within 4 weeks of beginning risperidone treatment and declined over time to within normal range. At study endpoint, mean prolactin levels were statistically significantly greater than baseline only in male participants but still <20 ng/mL, which is within the normal range. Twenty participants experienced mild or moderate extrapyramidal symptoms, although none withdrew for this reason. CONCLUSIONS: Risperidone, administered as an oral solution at a mean dose of 1.38 mg/d (range: 0.02-0.06 mg/kg/d) for 1 year, was well tolerated, safe, and showed maintenance of effect in the treatment of disruptive behavior disorders in children aged 5 to 12 years with subaverage IQs.
2002
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1542/peds.110.3.e34" target="_blank" rel="noreferrer">10.1542/peds.110.3.e34</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2002
Antipsychotic Agents/therapeutic use
Backlog
Binder C
Child
Child Behavior Disorders/complications/drug therapy
Dopamine Antagonists/therapeutic use
Female
Fisman S
Humans
Journal Article
Male
Mental Retardation/complications
Non-U.S. Gov't
Pediatrics
Research Support
Risperidone/therapeutic use
Serotonin Antagonists/therapeutic use
Snyder R
Turgay A
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1053/spen.2001.29477" target="_blank" rel="noreferrer">http://doi.org/10.1053/spen.2001.29477</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Sleep disorders in children with neurologic diseases
Publisher
An entity responsible for making the resource available
Seminars In Pediatric Neurology
Date
A point or period of time associated with an event in the lifecycle of the resource
2001
Subject
The topic of the resource
Child; Humans; Preschool; Q3 Literature Search; Nervous System Diseases/complications; Diagnosis; Differential; Anticonvulsants/therapeutic use; Sleep Disorders/etiology; Blindness/complications; Epilepsy/complications; Headache/complications; Melatonin/therapeutic use; Mental Retardation/complications; Muscular Dystrophies/complications
Creator
An entity primarily responsible for making the resource
Zucconi M; Bruni O
Description
An account of the resource
Pediatric neurologic diseases are often associated with different kinds of sleep disruption (mainly insomnia, less frequently hypersomnia or parasomnias). Due to the key-role of sleep for development, the effort to ameliorate sleep patterns in these children could have important prognostic benefits. Study of sleep architecture and organization in neurologic disorders could lead to a better comprehension of the pathogenesis and a better treatment of the disorders. This article focuses on the following specific neurologic diseases: nocturnal frontal lobe epilepsy and abnormal motor behaviors of epileptic origin, evaluating differential diagnosis with parasomnias; achondroplasia, confirming the crucial role of craniofacial deformity in determining sleep-disordered breathing; neuromuscular diseases, mainly Duchenne's muscular dystrophy and myotonic dystrophy; cerebral palsy, evaluating either the features of sleep architecture and the importance of the respiratory problems associated; headaches, confirming the strict relationships with sleep in terms of neurochemical and neurobehavioral substrates; and finally a review on the effectiveness of melatonin for sleep problems in children with neurologic syndromes and mental retardation, blindness, and epilepsy.
2001
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1053/spen.2001.29477" target="_blank" rel="noreferrer">10.1053/spen.2001.29477</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2001
Anticonvulsants/therapeutic use
Backlog
Blindness/complications
Bruni O
Child
Diagnosis
Differential
Epilepsy/complications
Headache/complications
Humans
Journal Article
Melatonin/therapeutic use
Mental Retardation/complications
Muscular Dystrophies/complications
Nervous System Diseases/complications
Preschool
Q3 Scoping Review Results
Seminars In Pediatric Neurology
Sleep Disorders/etiology
Zucconi M
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1055/s-2007-973701" target="_blank" rel="noreferrer">http://doi.org/10.1055/s-2007-973701</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Follow-up in children with Joubert syndrome
Publisher
An entity responsible for making the resource available
Neuropediatrics
Date
A point or period of time associated with an event in the lifecycle of the resource
1997
Subject
The topic of the resource
Child; Cross-Sectional Studies; Female; Humans; infant; Male; Adult; Follow-Up Studies; Disease Progression; adolescent; Preschool; Syndrome; Newborn; retrospective studies; Disease Specific; Mental Retardation/complications; Ataxia/diagnosis/genetics/physiopathology; Cerebellum/abnormalities; Developmental Disabilities/diagnosis/genetics/physiopathology; Facies; Kidney Diseases/complications; Mesencephalon/abnormalities; Muscle Hypotonia/diagnosis/genetics/physiopathology; Ocular Motility Disorders/complications; Respiration Disorders/complications; Survivors/classification
Creator
An entity primarily responsible for making the resource
Steinlin M; Schmid M; Landau K; Boltshauser E
Description
An account of the resource
Although Joubert syndrome (JS) was first reported in 1969 by Joubert et al (21), the long-term outcome is not yet documented. We report 19 children (4 pairs of siblings) from a single institution diagnosed with JS. Nine children were last seen between ages 10 and 18 years, seven between ages 1 and 4 years. Three children died before 3 years of age, showing marked breathing problems and minimal development. The 16 surviving children showed variable motor development, walking was typically achieved between 2 and 10 years, two children did not learn to walk. Cognitive development showed four with development quotient (DQ) of 30 or less and nine with DQ of 60-85, the others could not be judged confidently. Siblings did not show similar development and sex was not predicting outcome. The following oculomotor problems were seen: mystagmus in 11, ocular motor apraxia in six, isolated ptosis in two, and vertical gaze palsy in three. Additional features were retinal involvement in eight and kidney involvement in four, in one of them after normal previous ultrasound. In conclusion development of children with JS can be split into distinct subgroups, with one group dying at a young age. Those who survive show variable motor and cognitive development and can be grouped into those with DQ of less than 30 or those with DQ between 60 and 85. Ophthalmological and renal involvement may change or develop over the years and should be followed carefully.
1997
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1055/s-2007-973701" target="_blank" rel="noreferrer">10.1055/s-2007-973701</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
1997
Adolescent
Adult
Ataxia/diagnosis/genetics/physiopathology
Backlog
Boltshauser E
Cerebellum/abnormalities
Child
Cross-sectional Studies
Developmental Disabilities/diagnosis/genetics/physiopathology
Disease Progression
Disease Specific
Facies
Female
Follow-up Studies
Humans
Infant
Journal Article
Kidney Diseases/complications
Landau K
Male
Mental Retardation/complications
Mesencephalon/abnormalities
Muscle Hypotonia/diagnosis/genetics/physiopathology
Neuropediatrics
Newborn
Ocular Motility Disorders/complications
Preschool
Respiration Disorders/complications
Retrospective Studies
Schmid M
Steinlin M
Survivors/classification
Syndrome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1111/j.1651-2227.1996.tb13954.x" target="_blank" rel="noreferrer">http://doi.org/10.1111/j.1651-2227.1996.tb13954.x</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Studies on nutrition in severely neurologically disabled children in an institution
Publisher
An entity responsible for making the resource available
Acta Paediatrica
Date
A point or period of time associated with an event in the lifecycle of the resource
1996
Subject
The topic of the resource
Child; Female; Humans; infant; Male; adolescent; Preschool; Nutritional Status; Newborn; Nervous System Diseases/complications; Brain Damage; Energy Intake; Epilepsy/complications; Mental Retardation/complications; Institutionalized; Nutrition Disorders/complications; Asphyxia Neonatorum/complications; Chronic/complications; Ferritin/blood; Growth Disorders/etiology; Hemoglobins/analysis; Selenium/blood; Vitamin D/blood; Vitamin E/blood
Creator
An entity primarily responsible for making the resource
Hals J; Ek J; Svalastog AG; Nilsen H
Description
An account of the resource
Severe neurological handicaps in children are frequently accompanied by growth retardation. We have studied 13 severely neurologically impaired children in an institution to see if their poor growth was related to a low intake of energy and nutrients, if this was reflected in biochemical nutritional parameters, and to modify their diet according to the results. The investigation showed low dietary intakes of energy and of several of the nutrients, with corresponding low Hb values and serum values of ferritin, selenium and vitamins E and D in some of the children. All the children were initially light for age, with catch-up growth after intervention. We conclude that severely disabled children are at high risk for under- and malnutrition, and that this may partly explain the growth retardation in the study group. To avoid the potential detrimental effects of malnutrition, it is important to aim at providing an optimal diet.
1996
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1111/j.1651-2227.1996.tb13954.x" target="_blank" rel="noreferrer">10.1111/j.1651-2227.1996.tb13954.x</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
1996
Acta Paediatrica
Adolescent
Asphyxia Neonatorum/complications
Backlog
Brain Damage
Child
Chronic/complications
Ek J
Energy Intake
Epilepsy/complications
Female
Ferritin/blood
Growth Disorders/etiology
Hals J
Hemoglobins/analysis
Humans
Infant
Institutionalized
Journal Article
Male
Mental Retardation/complications
Nervous System Diseases/complications
Newborn
Nilsen H
Nutrition Disorders/complications
Nutritional Status
Preschool
Selenium/blood
Svalastog AG
Vitamin D/blood
Vitamin E/blood